GEORGE HUTTON to Middle Aged
This is a "connection" page, showing publications GEORGE HUTTON has written about Middle Aged.
Connection Strength
0.272
-
Financial and economic costs of healthcare-associated infections in Africa. J Hosp Infect. 2024 Aug; 150:1-8.
Score: 0.053
-
The concurrence of multiple sclerosis and glioblastoma. Mult Scler Relat Disord. 2021 May; 50:102877.
Score: 0.042
-
Comparative effectiveness and safety of glatopa and copaxone in patients with multiple sclerosis. Mult Scler Relat Disord. 2025 Dec; 104:106750.
Score: 0.014
-
Comparative effectiveness of high-efficacy and moderate efficacy disease-modifying agents in reducing the annualized relapse rates among multiple sclerosis patients in the United States. Prev Med. 2025 Jan; 190:108180.
Score: 0.014
-
Infection Risk Associated with High-Efficacy Disease-Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study. Clin Pharmacol Ther. 2025 Feb; 117(2):561-569.
Score: 0.014
-
Factors associated with the initiation of high-efficacy disease-modifying agents over moderate-efficacy disease-modifying agents in multiple sclerosis. Mult Scler Relat Disord. 2024 Nov; 91:105896.
Score: 0.014
-
Frequency, characteristics, predictors and treatment of relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Mult Scler Relat Disord. 2024 Jul; 87:105672.
Score: 0.013
-
Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis. Mult Scler Relat Disord. 2024 May; 85:105539.
Score: 0.013
-
Health-related quality of life of patients with multiple sclerosis: Analysis of ten years of national data. Mult Scler Relat Disord. 2022 Oct; 66:104019.
Score: 0.012
-
FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS. Mult Scler Relat Disord. 2022 Apr; 60:103703.
Score: 0.011
-
Clinical Reasoning: A 57-Year-Old Man With Stepwise Progressive Paraparesis, Sensory Loss, Urinary Retention, and Constipation. Neurology. 2022 02 01; 98(5):e555-e560.
Score: 0.011
-
Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records. Mult Scler Relat Disord. 2020 Oct; 45:102334.
Score: 0.010
-
Marginal Health Care Expenditure Burden Among U.S. Civilian Noninstitutionalized Individuals with Multiple Sclerosis: 2010-2015. J Manag Care Spec Pharm. 2020 Jun; 26(6):741-749.
Score: 0.010
-
Histogram analysis of apparent diffusion coefficient and fluid-attenuated inversion recovery in discriminating between enhancing and nonenhancing lesions in multiple sclerosis. Clin Imaging. 2020 Jan; 59(1):13-20.
Score: 0.010
-
High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report. JAMA Neurol. 2015 Feb; 72(2):159-69.
Score: 0.007
-
IFN-? induces the proliferation of CD4+CD25+Foxp3+ regulatory T cells through upregulation of GITRL on dendritic cells in the treatment of multiple sclerosis. J Neuroimmunol. 2012 Jan 18; 242(1-2):39-46.
Score: 0.006
-
Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology. 2009 Feb 10; 72(6):535-41.
Score: 0.005
-
Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data. Mult Scler. 2008 Apr; 14(3):370-82.
Score: 0.004
-
Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Jun; 39(11):705-9.
Score: 0.004
-
Costs attributable to AIDS at household level in Chad. AIDS Care. 2004 Oct; 16(7):808-16.
Score: 0.003
-
Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by interferon beta in multiple sclerosis. Mult Scler. 2004 Oct; 10(5):499-506.
Score: 0.003